People: PDI Inc (PDII.OQ)
PDII.OQ on NASDAQ Stock Exchange Global Market
4.76USD
1 Aug 2013
4.76USD
1 Aug 2013
Price Change (% chg)
$0.11 (+2.37%)
$0.11 (+2.37%)
Prev Close
$4.65
$4.65
Open
$4.71
$4.71
Day's High
$4.78
$4.78
Day's Low
$4.71
$4.71
Volume
5,946
5,946
Avg. Vol
23,000
23,000
52-wk High
$8.25
$8.25
52-wk Low
$3.82
$3.82
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Gerald Belle |
66 | 2010 | Independent Chairman of the Board |
Nancy Lurker |
2008 | Chief Executive Officer, Director | |
Jeffrey Smith |
65 | 2006 | Chief Financial Officer, Executive Vice President, Treasurer |
Gerald Melillo |
51 | 2012 | President - Sales Services |
Jo Saitta |
45 | 2011 | Chief Information Officer, General Manager of Group DCA, LLC |
John Federspiel |
58 | 2001 | Independent Director |
Veronica Lubatkin |
49 | 2008 | Independent Director |
Jack Stover |
59 | 2005 | Independent Director |
Stephen Sullivan |
65 | 2004 | Independent Director |
Melody Carey |
Co-President - Rx Communications |
Biographies
| Name | Description |
|---|---|
Gerald Belle |
Mr. Gerald P. Belle is Independent Chairman of the Board of PDI Inc. He has been a director since April 2008, is the Chairman of the Board. From 2004 until his retirement in November 2007, Mr. Belle served as Executive Chairman of Merial Ltd., a global animal health company that was a joint venture between sanofi-aventis and Merck & Co. Prior to that, Mr. Belle served as President and Chief Executive Officer, North America Pharmaceuticals for Aventis, Inc. He retired after 35 years of service at Aventis and its predecessor companies. Mr. Belle is chairman of the board of directors of Myrexis Inc., formerly known as Myriad Pharmaceuticals, Inc., a publicly held biopharmaceutical company. He was a member of the board of directors of Myriad Genetics, Inc., a publicly-traded genetics diagnostic company, from November 2007 through November 2009. Mr. Belle earned a B.S.B.A. in Marketing from Xavier University in 1968 and an M.B.A. from Northwestern University in 1969. |
Nancy Lurker |
Ms. Nancy S. Lurker is Chief Executive Officer, Director of PDI Inc. Prior to joining PDI, Ms. Lurker was senior vice-president and chief marketing officer for Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a product portfolio in multiple therapeutic areas from 2006 to 2007. Prior to that, she served as president and chief executive officer of ImpactRx, Inc. from 2003 to 2006, a privately owned company offering among its services the evaluation of the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest prescribing physicians. From 2000 to 2003, Ms. Lurker served as group vice president-global primary care products for Pharmacia Corporation, where she led a business unit that commercialized drugs for urology, cardiovascular, central nervous system, respiratory and women's health. She was also a member of Pharmacia's U.S. executive management committee, the group responsible for managing all U.S.-based profits as well as all U.S. management policies. Prior to her employment at Pharmacia Corporation, Ms. Lurker spent 14 years at Bristol-Myers Squibb. During her 14 years at Bristol-Myers Squibb, Ms. Lurker rose from senior sales representative at Mead Johnson to various product management and business development positions, ultimately becoming senior director-worldwide cardiovascular franchise management. Ms. Lurker was a member of the board of directors of Elan Pharmaceuticals during 2005 and 2006 and of ConjuChem Biotechnologies Inc. from 2004 to 2006. Since 2011, Ms. Lurker has been a member of the board of directors of Auxilium Pharmaceuticals, Inc. a publicly held company. Ms. Lurker received a B.S. in Biology with high honors from Seattle Pacific University and an M.B.A. from the University of Evansville in Evansville, Indiana. |
Jeffrey Smith |
Mr. Jeffrey E. Smith is Chief Financial Officer, Executive Vice President, Treasurer of PDI Inc. He joined the Company as Executive Vice President, Chief Financial Officer and Treasurer in May 2006. During the period June through November 2008 he served as Interim Chief Executive Officer of PDI. Prior to joining PDI, Mr. Smith was senior vice president, finance and chief financial officer of Pliva, Inc., a specialty generic pharmaceutical company from November 2002 to May 2006. From 1985 to 2002, Mr. Smith served in various executive positions with Alpharma, Inc., a global specialty pharmaceutical company. While with Alpharma, Inc., Mr. Smith was executive vice president, finance and chief financial officer and, for a three-year period, was responsible for worldwide operations while serving as acting president and member of the office of the chief executive. Mr. Smith is a Certified Public Accountant who began his career with Coopers & Lybrand, now PricewaterhouseCoopers. Mr. Smith received his B.S. from Fairleigh Dickinson University. |
Gerald Melillo |
Mr. Gerald R. Melillo, Jr., has been appointed as President - Sales Services of PDI, Inc., effective 22 October 2012. Melillo is a biopharmaceutical industry veteran who joined PDI in October 2011. Previously, he was the General Manager for the Southeast Operating Unit for Novartis Pharmaceuticals Corporation, where he was accountable for the operating unit's commercial activities. From 2004 to 2008 at Novartis, he was vice president of the ABGIU Business Franchise, responsible for marketing and strategic planning for key in-line brands, multiple brand launches, and key partnerships and joint ventures. Prior to that, he spent 15 years at Pharmacia, Inc. and Upjohn with increasing roles of responsibilities in sales and marketing. Mr. Melillo received his B.S. in Chemistry from Eckerd College, St. Petersburg, Fla. |
Jo Saitta |
Ms. Jo Ann Saitta is Chief Information Officer of PDI Inc and General Manager of Group DCA, LLC, a subsidiary of PDI Inc. She joined the Company in 2005 as VP, Information Technology Business Partner and brings over twenty years of experience in Information Technology strategic planning, execution, and management. She currently holds the positions of Chief Information Officer for PDI and General Manager of Group DCA, LLC, a digital communications subsidiary of PDI. Ms. Saitta is responsible for all Field Sales technology including sales force automation, data management, and the integration of multi channel solutions to optimize product sales. As General Manager of Group DCA, Ms. Saitta is accountable for growth of the digital content product line and its operations, development of mobile apps, and Group DCA's proprietary healthcare professional panel of physicians. Prior to joining PDI, Ms. Saitta served as Director, Relationship Management at Prudential Financial, Corporate Technology Services division and previously held various management and technical positions at IBM Global Services. Ms. Saitta holds two Bachelor degrees from Rutgers University and a Masters in Computer Science from New Jersey Institute of Technology. |
John Federspiel |
Mr. John Federspiel is Independent Director of PDI Inc. He has been a director since October 2001 and is the Chairman of the Nominating and Corporate Governance Committee of the Company. Mr. Federspiel is president of Hudson Valley Hospital Center, a 128-bed, short-term, acute care, not-for-profit hospital in Westchester County, New York. Prior to joining Hudson Valley Hospital in 1987, Mr. Federspiel spent 10 years in health administration, holding a variety of executive leadership positions. Mr. Federspiel has served as an appointed member of the State Hospital Review and Planning Council, and has served as chairman of the Northern Metropolitan Hospital Association. Mr. Federspiel received a B.S. degree from Ohio State University in 1975 and an M.B.A. from Temple University in 1977. |
Veronica Lubatkin |
Ms. Veronica A. Lubatkin CPA., is Independent Director of PDI Inc. She has been a director since November 2008. She is currently the executive vice president and chief financial officer of RailWorks Corporation, which she joined in July 2010. From 2007 to March 2009, Ms. Lubatkin was executive vice president and chief financial officer of Par Pharmaceutical Companies, Inc. and previously served as Par Pharmaceutical Companies' vice president and controller. Prior to joining Par Pharmaceutical Companies in April 2006, Ms. Lubatkin served in various positions at Schering-Plough Corporation from 1997 through 2006, including as executive director of strategic alliances for the cholesterol joint venture between Schering-Plough and Merck and as senior director of finance for Schering-Plough's global animal health business. Prior to joining Schering-Plough, Ms. Lubatkin was finance director for Neuman Distributors, Inc., formerly a U.S. pharmaceutical wholesaler. She began her career with Arthur Anderson in 1985. Ms. Lubatkin earned a B.A. degree in Accounting from Pace University in 1985 and is a Certified Public Accountant. |
Jack Stover |
Mr. Jack E. Stover is Independent Director of PDI Inc. He has been a director since August 2005, is Chairman of the Audit Committee of the Company. Since early 2009, Mr. Stover has served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Since July 2010, Mr. Stover has been a member of the Board of Influmedix Inc., a privately held biotechnology company focused on developing new treatments for influenza infection. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc., a publicly held company, from 2005 to 2008 and a member of the board of directors of Influmedix, Inc., a privately held company, from 2010 to 2011. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women's pharmaceutical company, Gynetics, Inc., and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant. |
Stephen Sullivan |
Mr. Stephen J. Sullivan is Independent Director of PDI Inc. He became a director in September 2004. Mr. Sullivan has been providing consulting services since 2010 and founded CRO Advisors LLC, a specialty consulting firm, in late 2010. Previously, Mr. Sullivan was the president and chief executive officer and a member of the Board of Directors of Harlan Laboratories, Inc., a privately held global provider of preclinical research tools and services, from February 2006 through January 2010, when he retired from that position. Prior to joining Harlan in 2006, Mr. Sullivan was a senior vice president of Covance, Inc. and the president of Covance Central Laboratories, Inc., a division of Covance. Prior to joining Covance, Mr. Sullivan was chairman and chief executive officer of Xenometrix, Inc., a biotechnology company with proprietary gene expression technology. He merged Xenometrix with Discovery Partners International. Prior to Xenometrix, Mr. Sullivan was vice president and general manager of a global diagnostic sector of Abbott Laboratories. Since May 2011, Mr. Sullivan has been the non-executive chairman of the board of directors of Molecular Imaging, Inc., a privately held company. Mr. Sullivan graduated from the University of Dayton, was a commissioned officer in the Marine Corps, and completed his M.B.A. in Marketing and Finance at Rutgers University. |
Melody Carey |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Gerald Belle |
-- |
Nancy Lurker |
1,377,040 |
Jeffrey Smith |
738,361 |
Gerald Melillo |
-- |
Jo Saitta |
448,775 |
John Federspiel |
-- |
Veronica Lubatkin |
-- |
Jack Stover |
-- |
Stephen Sullivan |
-- |
Melody Carey |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Gerald Belle |
0 | 0 |
Nancy Lurker |
0 | 0 |
Jeffrey Smith |
0 | 0 |
Gerald Melillo |
0 | 0 |
Jo Saitta |
0 | 0 |
John Federspiel |
0 | 0 |
Veronica Lubatkin |
0 | 0 |
Jack Stover |
0 | 0 |
Stephen Sullivan |
0 | 0 |
Melody Carey |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LUBATKIN VERONICA A |
10,068 | $4.47 |
SULLIVAN STEPHEN J |
10,068 | $4.47 |
STOVER JACK E |
10,068 | $4.47 |
FEDERSPIEL JOHN C |
10,068 | $4.47 |
BELLE GERALD P |
13,423 | $4.47 |
LURKER NANCY S |
51,320 | $5.44 |
MELILLO GERALD R JR |
10,997 | $5.44 |
SMITH JEFFREY EDWARD |
25,660 | $5.44 |
SMITH JEFFREY EDWARD |
7,310 | $7.43 |
LURKER NANCY S |
16,279 | $7.43 |
SAITTA JO ANN |
4,642 | $7.43 |
SAITTA JO ANN |
276 | $7.81 |
FEDERSPIEL JOHN C |
5,577 | $8.07 |
BELLE GERALD P |
7,435 | $8.07 |
STOVER JACK E |
5,577 | $8.07 |
LUBATKIN VERONICA A |
5,577 | $8.07 |
SULLIVAN STEPHEN J |
5,577 | $8.07 |
SMITH JEFFREY EDWARD |
6,367 | $7.00 |
SAITTA JO ANN |
2,877 | $7.00 |
LURKER NANCY S |
50,702 | $6.41 |
SMITH JEFFREY EDWARD |
22,624 | $6.63 |
MELILLO GERALD R JR |
9,427 | $6.63 |
MELILLO GERALD R JR |
4,000 | $6.59 |

